Brought to you by
Breastfeeding Decreases Risk of Type 2 Diabetes
Breastfeeding may not only benefit the infant, but have a positive impact on the mother as well, according to a new cohort study published in the September issue of The American Journal of Medicine. Researchers found a significantly increased risk of type 2 diabetes (T2D) in mothers who breastfed their infants for less than 1 month, a risk that is independent of physical activity and body mass index later in life.
Eleanor Bimla Schwarz, MD, MS, of the University of Pittsburgh, Pennsylvania, and colleagues studied 2233 women aged 40 to 78 years, 1828 of whom were mothers. Data on breastfeeding and T2D were collected through questionnaires; odds ratios (ORs) were calculated to evaluate the association between breastfeeding and T2D.
The results showed that mothers who exclusively breastfed for at least 1 month compared with nonmothers had a nonsignificant OR of 1.01, but the OR of mothers who did not exclusively breastfeed for at least 1 month compared with mothers who did was significant at 1.38. Increased consistency of breastfeeding was also associated with a lower OR for developing T2D.
The authors theorize that this increased risk of developing T2D may be due to retaining visceral fat, which is lost when mothers breastfeed. This visceral fat is more metabolically active than fat deposits in other parts of the body and can influence insulin resistance mechanisms. While the study may have produced some recall bias because of the questionnaire format, the authors conclude that the results highlight the need for more support of breastfeeding from “women’s health care providers as well as legislators and workplace policymakers.”
Major Depression: A Risk for Foot Ulcers?
Major depression is associated with a 2-fold higher risk of incident diabetic foot ulcers, according to a study published in the August issue of The American Journal of Medicine. This is the first study to examine the association of depression and diabetic foot ulcers. Lisa Williams, MD, MS, of the University of Washington in Seattle and colleagues designed a prospective cohort study that enrolled 3474 adults with type 2 diabetes and no history of diabetic foot ulcers or amputations.
The researchers administered a questionnaire to assess for a major or minor depression diagnosis, and then conducted a chart review over an average of 4 years to screen for diabetic foot ulcers. Adjusted hazard ratios (HRs) for diabetic foot ulcers were then calculated. The researchers found that patients with major depression had an adjusted HR of 2.17 compared with patients with no depression. The HR in patients with minor depression was not significant.
Dr. Williams and coauthors stipulate that this increased risk may be due to peripheral neuropathy, which has been seen more in patients with major depression. Peripheral neuropathy can cause altered or complete loss of sensation in the feet, so foot wounds can go unnoticed. They also theorize that diabetic patients with coexisting major depression tend to have poorer glycemic control, are less adherent with medications, and have a more sedentary lifestyle than patients with no depression.
There were some important limitations of this study, including lack of evaluation of depression past baseline, lack of diagnosis of peripheral neuropathy throughout the study, and enrollment only from Washington state, which limits generalizations for the population with diabetes as a whole.
Aspirin Therapy in Patients with Diabetes Reevaluated
A joint statement in June 2010 from the American Diabetes Association (ADA), the American Heart Association (AHA), and the American College of Cardiology (ACC) calls for stricter guidelines for initiating low-dose aspirin therapy in patients with diabetes. The guidelines recommend that low-dose aspirin only be started in men with diabetes older than 50 years and women with diabetes older than 60 years who have 1 or more additional major risk factor for cardiovascular events, such as smoking, dyslipidemia, hypertension, family history of disease, or albuminuria. Previous recommendations were to start low-dose aspirin therapy in any individual with diabetes older than 40 years, regardless of additional risk factors.
The new recommendation is based on analysis of trials evaluating outcomes with aspirin in primary prevention of cardiovascular disease (CVD) in patients with diabetes, particularly the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes and the Prevention of Progression of Arterial Disease and Diabetes, neither of which showed any significant benefit to aspirin therapy.
The ADA/AHA/ACC statement notes that the benefits of aspirin in preventing CVD must be matched with the risks of aspirin therapy, particularly the risk of developing bleeding.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs